期刊文献+

抗癌药物马赛替尼的合成工艺优化 被引量:1

Improved Synthesis of Anti-Cancer Drug Masitinib
下载PDF
导出
摘要 对现有文献报道的马赛替尼合成工艺进行优化改进.以2-甲基-5-硝基苯胺为原料,经缩合、噻吩环化、还原氢化、酰化等反应制备马赛替尼,产物结构经电喷雾质谱(ESI-MS),核磁共振氢谱(~1 H-NMR),核磁共振碳谱(^(13)C-NMR)等确证,并对其中的合成条件进行优化对比研究.结果表明:优化工艺后,马赛替尼的总收率为37.3%(以2-甲基-5-硝基苯胺计),与文献报道的工艺相比,提高了9%;优化后的工艺具有反应时间短、成本低、收率高等特点,更易应用于工业化生产. The synthesis process of masitinib which was reported in the literature was improved.Masitinib was synthesized by using 2-methyl-5-nitroaniline as a raw material,via condensation,cyclization,hydrogenation and acylation etc,its structure was confirmed by electrospray ionization mass spectrometry(ESI-MS),proton nuclear magnetic resonance(1H-NMR)and carbon 13 nuclear magnetic resonance(13 C-NMR),and the reaction conditions of some steps were optimized.The results show that the yield of masitinib after optimization was up to 37.3%(in terms of 2-methyl-5-nitroaniline),which is 9%higher than that reported in literature;the optimized process has the characteristics such as short reaction time,low cost and high yield,and it′s easier to apply to industrial production.
作者 张嘉颖 裘京晓 黄程勇 吴振 王立强 ZHANG Jiaying;QIU Jingxiao;HUANG Chengyong;WU Zhen;WANG Liqiang(School of Biomedical Sciences,Huaqiao University,Quanzhou 362021,China;Affiliated Hospital,Beijing International Studies University,Beijing 100024,China;School of Pharmaceutical Sciences,Xiamen University,Xiamen 361102,China)
出处 《华侨大学学报(自然科学版)》 CAS 北大核心 2019年第2期215-220,共6页 Journal of Huaqiao University(Natural Science)
基金 国家重点研发计划项目(2016YFE0101700) 华侨大学研究生科研创新能力培育计划资助项目(17014071021)
关键词 马赛替尼 抗癌药物 2-甲基-5-硝基苯胺 工艺优化 masitinib anti-cancer drug 2-methyl-5-nitroaniline optimization
  • 相关文献

参考文献2

二级参考文献9

  • 1Roskoski R Jr.Signaling by Kit protein tyrosine kinase-the stem cell factor receptor. Biochemical and Biophysical Research Communications . 2005 被引量:1
  • 2J Tebib,X Mariette,P Bourgeois.Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Research and Therapy . 2009 被引量:1
  • 3Moussy A,Reginault P,Bellamy F,et al.Process for thesynthesis of 2-aminothiazole compounds as kinase inhibitors. WO,2008098949 . 2008 被引量:1
  • 4MAHBOOBI S,DOVE S,SELLMERe A,et al.Design of chim-eric histone deacetylase-and tyrosine kinase-inhibitors:A Seriesof Imatinib hybrides as potent inhibitors of wild-type and mutantBCR-ABL,PDGF-Rβ,and histone deacetylases. Journal of Medicinal Chemistry . 2009 被引量:1
  • 5TASTA U.KIT mutations in cancer and their treatment withprotein kinase inhibitors. Drugs of the Future . 2008 被引量:1
  • 6LENNARTTSON J,JELACIC T,LINNEKIN D,et al.Normaland oncogenic forms of the receptor tyrosine kinase KIT. Stem Cells . 2005 被引量:1
  • 7HUMBERT M F,BLAY D,GARCIA G,et al.Masitinib,ac-KIT/PDGF receptor tyrosine kinase inhibitor,improvesdisease control in severe conticoteroid-dependent asthmatics. Allergy . 2009 被引量:1
  • 8MOUSSY A,KINET J P.Use of c-kit inhibitors for treatingtype II diabetes. WO,2005 016323 . 2005 被引量:1
  • 9CIUFOLINI M,WERMUTH C,GIELTHEN B,et al.2-(3-Aminoaryl)amino-4-aryl-thiazoles and their use as c-kitinhibitors. WO,2004 014903 . 2004 被引量:1

共引文献2

同被引文献3

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部